Compugen to Participate in H.C. Wainwright Investment Conference

HOLON, Israel, Sept. 8, 2026 /CourierPR/ -- Compugen, a clinical-stage cancer immunotherapy company, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, set to take place in New York City from September 14 to 16, 2026.

Compugen focuses on developing innovative immunotherapy treatments using its AI-powered computational discovery platform, Unigen™. The company’s pipeline includes several promising candidates, such as COM701, a potential first-in-class anti-PVRIG antibody. Currently, COM701 is being evaluated in the MAIA-ovarian trial as a single agent in maintenance therapy for relapsed platinum-sensitive ovarian cancer.

Additionally, the company is collaborating with AstraZeneca on the development of rilvegostomig, a PD-1/TIGIT bispecific antibody. This therapy is being evaluated in multiple clinical trials, including Phase 3, Phase 2, and Phase 1 trials. Another key asset, GS-0321 (previously COM503), is a high-affinity antibody that blocks the interaction between IL-18 binding protein and IL-18. GS-0321 is being licensed to Gilead and is currently undergoing a Phase 1 clinical trial.

Compugen is also advancing early-stage research programs aimed at enhancing anti-cancer immunity through various mechanisms. The company’s shares are listed on the Nasdaq and Tel Aviv Stock Exchange under the ticker CGEN.

This participation in the H.C. Wainwright conference is a significant opportunity for Compugen to present its latest developments and engage with investors and stakeholders. Compugen’s management will be available for one-on-one meetings with interested parties throughout the conference, providing an opportunity for in-depth discussions.